Oliver Mobasser

Oliver's representative experience includes advising:

• LEO Pharma on its strategic partnership with Gilead Sciences to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases
• Rhythm Pharmaceuticals on its global licensing agreement with LG Chem Life Sciences (LG Chem), a Korean life sciences company, for LB54640, an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist, now in Phase 2 clinical trials
• GSK on:
  • A strategic global collaboration and licensing agreement with Alector for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies for a range of neurodegenerative diseases
  • A global license and collaboration with SpringWorks Therapeutics for development and commercialization of SpringWorks’ nirogacestat product and GSK’s Blenrep product 
  • Several early-stage clinical trial, collaboration, development, and supply arrangements
  • The divestment of its Prevacid 24HR business to Perrigo Company
  • The divestment of assets relating to the Bialcol and Cibalgina brands in Italy to Vemedia
  • The divestment of five over-the-counter dermatology brands and one pediatric cough remedy brand to the STADA Group
  • The divestment of four established over-the-counter brands in eight countries to Pharma SGP
• Swedish Orphan Biovitrum AB (publ) (Sobi™) on matters including:
  • A global (ex-US) development agreement and supply agreement for the enFuse Injector, for the subcutaneous delivery of Aspaveli (pegcetacoplan)
  • A strategic licensing agreement with Selecta Biosciences for SEL-212, a phase-3 ready therapy for the treatment of chronic refractory gout, with a deal value of approximately US$730 million
  • A strategic licensing and collaboration agreement with Apellis Pharmaceuticals for co-development and exclusive ex-US commercialisation rights for systemic pegcetacoplan
  • Streamlining and simplifying the contractual economics for nirsevimab through a new royalty agreement with Sanofi and the termination of its participation agreement with AstraZeneca 
  • Its US$1.7 billion acquisition of CTI BioPharma Corp, a biopharmaceutical company focused on blood-related cancers and rare diseases 
• Norgine, a Netherlands-based specialty pharmaceutical company, on matters including:
  • An exclusive licensing and supply agreement with X4 Pharmaceuticals (Nasdaq: XFOR) to commercialize Mavorixafor in Europe, Australia, and New Zealand
  • Its US$2 billion sale to Goldman Sachs
• Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with its licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, to commercialise and launch Linzagolix, an oral GnRH antagonist
• Astorg and OPEN Health on data protection matters related to the acquisition of The CM Group, an integrated commercialization platform
• Lindsay Goldberg, on data protection matters related to its investment in MMS Holdings, a leading data-focused contract research organization
• A consortium of Astorg Asset Management, Nordic Capital, Novo Holdings — and their portfolio company eResearchTechnologies, on the data privacy aspects of its merger with Bioclinica, a technological and scientific leader in clinical imaging
• Frontier Medicines on the data privacy aspects of its global partnership with AbbVie to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein target
• BC Partners on IP, contracts, data protection and regulatory matters related to the acquisition of a majority interest in Synthon International Holding B.V., Various pharmaceutical and medical technology companies on agreements for the conduct of clinical trials in the EU, including GDPR compliance aspects
• Leadiant Biosciences on the sale of its assets relating to Revcovi, a pharmaceutical product for the treatment of a rare immunodeficiency disease, to Chiesi Farmaceutici
• Novo Holdings A/S on its acquisition of BBI Group, a leading supplier of products and services, to the global diagnostics and life sciences industries
• Acino Pharma in relation to its purchase of a portfolio of over-the-counter and prescription pharmaceutical products in the Near East, Middle East, and Africa for a total value in excess of US$200 million
• Oasmia Pharmaceutical AB on its global strategic partnership for the development and commercialization of its proprietary anticancer product, Apealea, with Elevar Therapeutics, with a deal value of approximately US$698 million
• Ligand Pharmaceuticals on its sale of Vernalis (R&D) Limited, a UK-based fragment and structure-based drug discovery research company, to HitGen
• Permira, on contracts, regulatory, and IP matters related to the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory, two leading providers of medicinal products derived from human blood plasma
• Permira on data protection, contracts, regulatory, and IP matters related to the acquisition of Quotient Sciences, a provider of contract development and manufacturing and contract research services to pharma and biotech companies
• Quotient Sciences on its acquisition of Arcinova, the UK based multiservice contract development and manufacturing organization